ISR’S NOVEL METHOD
The gold standard for the millions already infected with HIV is antiretroviral drugs targeting virus replication, integration and release.
No current treatments exploit the immune system´s potential to treat an established HIV/AIDS infection. ISR´s novel method introduces three key opportunities:
ISR’s technology will provide a therapy with a unique mechanism of action beyond the risk of viral mutation - an attractive resistance profile which does not require co-dosing with a boosting agent.
The long-term financial aspects of treating HIV patients with costly dietary supplements and other medical treatments may be reduced - a major health economy impact.
New patents based on the second generation of ISR048 (ISR049), data protection of the use of ISR048 and existing IP defining the method and means for treating viral disease, will position ISR at the competitive edge at the time many companies will lose market protection.
KEY POINTS
HIV continues to be a major global public health issue with a significant burden of disease
There is no cure for HIV infection
New and more effective therapies are still needed
No alternative treatment in cases of ART resistance and ART intolerance representing 8% - 14% receiving ART treatment (Business opportunity $200-300 MUSD)
Several of the HIV leaders will begin losing patent and market protection in 2017
In 2016, four of the top 10 best selling HIV drugs will still expand sales
New international WHO guidelines - early treatment
16 сен 2024
